Skip to main content
Premium Trial:

Request an Annual Quote

54gene Raises $25M in Series B Round

NEW YORK — African health technology company 54gene said on Thursday that it has closed a $25 million Series B financing round.

The round was led by Cathay AfricInvest Innovation Fund and included participation from Adjuvant Capital, KdT Ventures, Plexo Capital, Endeavor Capital, and Ingressive Capital.

54gene was founded in 2019 to gather genomic, phenotypic, and other data relevant to Africans to improve healthcare in this population. In 2020, the company raised $15 million in a Series A round, and this year it began pursuing research and pharmaceutical partnerships after having hit an initial milestone of 100,000 African participants for its biobank.

54gene said it will use the Series B funding to expand its sequencing, target identification, and target validation capabilities, as well as to run precision medicine clinical trials. The company said it will also use the money to expand its genomics and molecular diagnostics division across Africa.

"In this round we have brought in partners that keep us true to our mission of equalizing healthcare and who can help us replicate our success throughout Africa," 54gene CEO Abasi Ene-Obong said in a statement. "We believe the world will benefit from an African global drug discovery company that leverages the deep insights found in genomics research in diverse populations and ensures true equity for the African population."

54gene said it has raised $45 million to date.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.